Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Lung Cancer
88%
Non Small Cell Lung Cancer
84%
Video-Assisted Thoracoscopic Surgery
80%
Segmentectomy
61%
Overall Survival
60%
Epithelioma
59%
Epidermal Growth Factor Receptor
57%
Progression Free Survival
53%
Epidermal Growth Factor Receptor Kinase Inhibitor
47%
Pneumonectomy
41%
Thymus Cancer
41%
Cancer Cell
38%
Combination Therapy
35%
Lymphocyte
34%
Neoplasm
34%
Hazard Ratio
32%
Mediastinal Tumor
29%
Computer Assisted Tomography
27%
Prognostic Factor
25%
Neutrophil
24%
Lung Tuberculosis
24%
Diseases
24%
Programmed Death-Ligand 1
24%
Esophageal Cancer
22%
Lung Adenocarcinoma
22%
Lobectomy
22%
Upregulation
22%
Brain Metastasis
21%
Thymic Carcinoma
21%
Chemoradiotherapy
20%
Osimertinib
19%
Esophagectomy
19%
Pulmonary Sequestration
19%
Cancer Therapy
19%
M2 Macrophages
19%
Radiomics
19%
Intensity Modulated Radiation Therapy
19%
Spontaneous Pneumothorax
19%
Cohort Analysis
19%
Metastatic Carcinoma
14%
Esophageal Squamous Cell Carcinoma
14%
Magnetic Resonance Imaging
14%
Proportional Hazards Model
14%
Postoperative Complication
14%
Lung Function
14%
Promoter Region
14%
Surgical Technique
13%
Lung
13%
Cancer
12%
Non-Small Cell Lung Cancer
12%
Pharmacology, Toxicology and Pharmaceutical Science
Non Small Cell Lung Cancer
100%
Lung Cancer
76%
Epidermal Growth Factor Receptor
64%
Progression Free Survival
50%
Neoplasm
44%
Epidermal Growth Factor Receptor Kinase Inhibitor
43%
Overall Survival
41%
Cancer Growth
36%
Combination Therapy
32%
Malignant Neoplasm
31%
Adverse Outcome
29%
Fibrosing Alveolitis
29%
Cohort Study
29%
Chemotherapy
28%
Diseases
27%
Protein Tyrosine Kinase Inhibitor
21%
Osimertinib
19%
Nintedanib
19%
Diethylstilbestrol
19%
Brain Metastasis
19%
Monotherapy
17%
Chemoradiation Therapy
13%
Programmed Death 1 Ligand 1
11%
Lung Adenocarcinoma
11%
Chemokine
10%
Tumor Growth
10%
Gefitinib
10%
Lung Nodule
9%
Chitosan
9%
Pembrolizumab
9%
Tumor Promotion
9%
Tumor Suppressor Protein
9%
Immune Checkpoint Inhibitor
9%
Colony Stimulating Factor 1
9%
Lung Emphysema
9%
DNA (Cytosine 5) Methyltransferase 1
9%
Drug Resistance
9%
Esophagus Cancer
9%
Galactosyltransferase Gene Knockout Pig
9%
Oncolytic Adenovirus
9%
Thrombospondin 1
9%
Protein P53
9%
Cyclin D1
9%
Pirfenidone
9%
STAT1 Protein
9%
Circulating Tumor DNA
9%
Bevacizumab
9%
Rapamycin
9%
Esophagus Fistula
9%
Vasculotropin
9%
Keyphrases
Lung Cancer
39%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
31%
Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor (EGFR-TKI)
29%
Thymoma
24%
Overall Survival
23%
Hazard Ratio
22%
M2 Macrophages
21%
EGFR mutation
20%
Combination Therapy
20%
Interleukin-33 (IL-33)
19%
ST2L
19%
Video-assisted Thoracoscopic Surgery
19%
Thymic Epithelial Tumors
19%
Completely Resected
19%
Anatomical Lung Resection
19%
Positive Feedback Loop
19%
Uniportal
19%
NF-B
19%
Mediastinal Tumor
19%
RAB37
19%
Chemotherapy Efficacy
19%
Non-small Cell Lung Cancer (NSCLC)
19%
Progression-free Survival
16%
Thymic Malignancy
14%
Neutrophil-to-lymphocyte Ratio
14%
Monotherapy
14%
Lung Cancer Cells
14%
Chest CT
13%
Survival Benefit
13%
Epidermal Growth Factor Receptor
13%
Tertiary Care Hospital
13%
Lung Cancer Progression
11%
T790M mutation
10%
Non-small Cell Lung Cancer Patients
10%
Confidence Interval
10%
Prognostic Factors
10%
M2 Macrophage Polarization
10%
Masaoka Stage
10%
Deep Learning Radiomics
9%
Multi-institutional Study
9%
Real-world Outcomes
9%
NSCLC Patients
9%
Allogeneic Transplantation
9%
Surgical Resection
9%
Channel-spatial Attention
9%
Gastric Stricture
9%
False Positive Reduction
9%
NnU-Net
9%
Taiwan
9%
Lung Nodule Segmentation
9%
